These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 21279990)

  • 1. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
    Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
    Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
    Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
    N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
    Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
    J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
    Scott DL
    Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The status of fostamatinib in the treatment of rheumatoid arthritis.
    Morales-Torres J
    Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Baluom M; Samara E; Grossbard EB; Lau DT
    J Clin Pharmacol; 2011 Sep; 51(9):1310-8. PubMed ID: 21209239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
    Nijjar JS; Tindell A; McInnes IB; Siebert S
    Rheumatology (Oxford); 2013 Sep; 52(9):1556-62. PubMed ID: 23861534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
    Boers M
    Arthritis Rheum; 2011 Feb; 63(2):329-30. PubMed ID: 21279987
    [No Abstract]   [Full Text] [Related]  

  • 12. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
    Bajpai M
    IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.
    Fleischmann RM; Damjanov NS; Kivitz AJ; Legedza A; Hoock T; Kinnman N
    Arthritis Rheumatol; 2015 Feb; 67(2):334-43. PubMed ID: 25385260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
    Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
    J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
    van Vollenhoven RF; Kinnman N; Vincent E; Wax S; Bathon J
    Arthritis Rheum; 2011 Jul; 63(7):1782-92. PubMed ID: 21452294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
    Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American College of Rheumatology hybrid measure for assessing efficacy of treatment in patients with refractory rheumatoid arthritis: comment on the article by Genovese et al.
    Felson DT
    Arthritis Rheum; 2011 Oct; 63(10):3181-2; author reply 3182. PubMed ID: 21769845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.